The DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
SGLT2 inhibitors in patients with heart failure: a comprehensive meta-analysis of five randomised controlled trials
Open accessAbstract
BACKGROUND: SGLT2 inhibitors are strongly recommended in guidelines to treat patients with heart failure with reduced ejection fraction, but their clinical benefits at higher ejection fractions are less well established. Two large-scale trials, DELIVER and EMPEROR-Preserved, in heart failure with mildly reduced or preserved ejection fraction have been done, providing power to examine therapeutic effects on cardiovascular mortality and in patient subgroups when combined with the earlier trials in reduced ejection fraction. METHODS: We did a prespecified meta-analysis of DELIVER and EMPEROR-Preserved, and subsequently included trials that enrolled patients with reduced ejection fraction (DAPA-HF and EMPEROR-Reduced) and those admitted to hospital with worsening heart failure, irrespective of ejection fraction (SOLOIST-WHF). Using trial-level data with harmonised endpoint definitions, we did a fixed-effects meta-analysis to estimate the effect of SGLT2 inhibitors on various clinical endpoints in heart failure The primary endpoint for this meta-analysis was time from randomisation to the occurrence of the composite of cardiovascular death or hospitalisation for heart failure. We assessed heterogeneity in treatment effects for the primary endpoint across subgroups of interest. This study is registered with PROSPERO, CRD42022327527. FINDINGS: Among 12 251 participants from DELIVER and EMPEROR-Preserved, SGLT2 inhibitors reduced composite cardiovascular death or first hospitalisation for heart failure (hazard ratio 0·80 [95% CI 0·73-0·87]) with consistent reductions in both components: cardiovascular death (0·88 [0·77-1·00]) and first hospitalisation for heart failure (0·74 [0·67-0·83]). In the broader context of the five trials of 21 947 participants, SGLT2 inhibitors reduced the risk of composite cardiovascular death or hospitalisation for heart failure (0·77 [0·72-0·82]), cardiovascular death (0·87 [0·79-0·95]), first hospitalisation for heart failure (0·72 [0·67-0·78]), and all-cause mortality (0·92 [0·86-0·99]). These treatment effects for each of the studied endpoints were consistently observed in both the trials of heart failure with mildly reduced or preserved ejection fraction and across all five trials. Treatment effects on the primary endpoint were generally consistent across the 14 subgroups examined, including ejection fraction. INTERPRETATION: SGLT2 inhibitors reduced the risk of cardiovascular death and hospitalisations for heart failure in a broad range of patients with heart failure, supporting their role as a foundational therapy for heart failure, irrespective of ejection fraction or care setting. FUNDING: None.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“These drug classes are recommended as glucose-lowering therapy for individuals with cardiovascular disease or risk factors6,7 on the basis of randomized clinical trial evidence demonstrating a reduction in cardiovascular events (SGLT2is and GLP-1RAs)14,15,16 or suggesting cardiovascular benefit (metformin and pioglitazone).17,18”
From Cardioprotective Glucose-Lowering Agents and Dementia Risk: A Systematic Review and Meta-Analysis (2025) · cites this paper as [15]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Large placebo-controlled trials have shown that sodium glucose co-transporter-2 (SGLT2) inhibitors reduce the risk of cardiovascular disease, and particularly hospitalisation for heart failure, in patients with type 2 diabetes at high risk of atherosclerotic cardiovascular disease, heart failure, or chronic kidney disease.”
From Impact of diabetes on the effects of sodium glucose co-transporter-2 inhibitors on kidney outcomes: collaborative meta-analysis of large placebo-controlled trials (2022) · cites this paper as [5]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“a large meta-analysis (308) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and the Effect of Sotagliflozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOIST-WHF) trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death,”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2025 (2025) · cites this paper as [308]
The cited source says what the claim attributes to it.
In the citing paper
“A large meta-analysis (297) including the EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and SOLOIST-WHF trials included 21,947 individuals and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, first hospitalization for heart failure, and all-cause mortality.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
The cited source says what the claim attributes to it.
In the citing paper
“The findings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all five trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2026 (2026) · cites this paper as [297]
In the citing paper
“Over the past decade, several large RCTs failed to achieve statistical significance with regard to effects on the primary outcomes in patients with HFpEF including: PEP-CHF (perindopril), CHARM-Preserved (candesartan), I-PRESERVE (irbesartan), TOPCAT (spironolactone), DIG Ancillary Trial (digoxin), and PARAGON-HF (sacubitril/valsartan). 477,[534][535][536][537][538]”
From 2023 ESC guidelines for the management of cardiovascular disease in patients with diabetes. (2023) · cites this paper as [535]
In the citing paper
“There is good evidence to support the use of SGLT2 inhibitors as a foundational therapy to prevent cardiovascular death or hospitalisation for heart failure in patients with heart failure, irrespective of ejection fraction or history of previous diabetes.1, 2, 3, 4, 5”
In the citing paper
“A large recent meta-analysis (227) including data from EMPEROR-Reduced, EMPEROR-Preserved, DAPA-HF, DELIVER, and Effect of Sotagli fl ozin on Cardiovascular Events in Patients With Type 2 Diabetes Post Worsening Heart Failure (SOLOISTWHF) included 21,947 patients and demonstrated reduced risk for the composite of cardiovascular death or hospitalization for heart failure, cardiovascular death, fi r”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
In the citing paper
“The fi ndings on the studied end points were consistent in both trials of heart failure with mildly reduced or preserved ejection fraction and in all fi ve trials combined.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [227]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure
McDonagh, T. A., Metra, M., Adamo, M., Gardner, R. S., Baumbach, A., Böhm, M., Burri, H., Butler, J., Čelutkienė, J., Chioncel, O., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab368 · Cited by 13,344
Self-citationDapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
Self-citationCardiovascular and renal outcomes with empagliflozin in heart failure
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., Januzzi, J., Verma, S., Tsutsui, H., Brueckmann, M., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022190 · Cited by 5,206
Empagliflozin in heart failure with a preserved ejection fraction
Anker, S. D., Butler, J., Filippatos, G., Ferreira, J. P., Bocchi, E., Böhm, M., Brunner–La Rocca, H.-P., Choi, D.-J., Chopra, V., Chuquiure-Valenzuela, E., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2107038 · Cited by 4,874
Self-citationDapagliflozin in Heart Failure with Mildly Reduced or Preserved Ejection Fraction
Solomon, S. D., McMurray, J. J. V., Claggett, B., de Boer, R. A., DeMets, D., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2206286 · Cited by 2,884
Self-citationSotagliflozin in patients with diabetes and recent worsening heart failure
Bhatt, D. L., Szarek, M., Steg, P. G., Cannon, C. P., Leiter, L. A., McGuire, D. K., Lewis, J. B., Riddle, M. C., Voors, A. A., Metra, M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2030183 · Cited by 1,868
Zannad, F., Ferreira, J. P., Pocock, S. J., Anker, S. D., Butler, J., Filippatos, G., Brueckmann, M., Ofstad, A. P., Pfarr, E., Jamal, W., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31824-9 · Cited by 1,408
McGuire, D. K., Shih, W. J., Cosentino, F., Charbonnel, B., Cherney, D. Z. I., Dagogo-Jack, S., Pratley, R., Greenberg, M., Wang, S., Huyck, S., et al. (2021) · JAMA Cardiology · doi:10.1001/jamacardio.2020.4511 · Cited by 1,235
2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary
Heidenreich, P. A., Bozkurt, B., Aguilar, D., Allen, L. A., Byun, J. J., Colvin, M. M., Deswal, A., Drazner, M. H., Dunlay, S. M., Evers, L. R., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2021.12.011 · Cited by 931
Self-citationSolomon, S. D., Anavekar, N. S., Skali, H., McMurray, J. J. V., Swedberg, K. B., Yusuf, S., Granger, C. B., Michelson, E. L., Wang, D., Pocock, S., et al. (2005) · Circulation · doi:10.1161/circulationaha.105.561423 · Cited by 873
Self-citation
Research works printed but not linked: 1
- Zannad, 2020, SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials, Lancet, 396, 819, 10.1016/S0140-6736(20)31824-9 · DOI · Paper page
Cited by
Sorted by citations
Items 301–400 of 1,000
Asil, H., Demiryürek, A. T., Düzen, İ. V., Buyukcelebi, O., Saracaloğlu, A., Demirkiran, C., & Demiryürek, Ş. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.176934 · Cited by 10
Mori, Y., Komura, T., Adomi, M., Yagi, R., Fukuma, S., Kondo, N., Yanagita, M., Duru, O. K., Tuttle, K. R., & Inoue, K. (2024) · Cardiovascular Diabetology · doi:10.1186/s12933-024-02478-7 · Cited by 12
New and future heart failure drugs
Haghighat, L., DeJong, C., & Teerlink, J. R. (2024) · Nature Cardiovascular Research · doi:10.1038/s44161-024-00576-z · Cited by 14
Zheng, R., Song, W., Lu, J. L., Yuan, M., Sun, X., & Lu, C. (2025) · Cardiovascular Diabetology · doi:10.1186/s12933-025-02600-3 · Cited by 11
Flausino, L. E., Carrasco, A. G. M., Furuya, T. K., Tuan, W., & Chammas, R. J. (2025) · BMC Cancer · doi:10.1186/s12885-025-13966-8 · Cited by 13
Clinical Assessment of People With Obesity: Focus on Adiposity-Related Multimorbidity
Bianchettin, R. G., Gawey, B. J., Acosta, A. J., Borlaug, B. A., Caples, S. M., Collazo–Clavell, M. L., Clark, M. M., Lara-Breitinger, K. M., Lerman, A., Lerman, L. O., et al. (2025) · Mayo Clinic Proceedings · doi:10.1016/j.mayocp.2025.02.021 · Cited by 13
GPLD1 Attenuates Heart Failure via Dual-Membrane Localization to Inhibit uPAR
Yu, W., Guo, Z., Liang, H., Ma, D., Lin, C., Li, Z., Yu, J., Ataran, A., Javaheri, A., Liu, Z., et al. (2025) · Circulation Research · doi:10.1161/circresaha.124.325623 · Cited by 12
Xia, J., Nong, Y., Teng, J., Mohammed, S. A., Liu, J., Pang, Y., Costantino, S., Ruschitzka, F. T., Hamdani, N., Abdellatif, M., et al. (2025) · iScience · doi:10.1016/j.isci.2025.113471 · Cited by 12
Osanami, A., Sato, T., Toda, Y., Shimizu, M., Kuno, A., Kouzu, H., Yano, T., Ohwada, W., Ogawa, T., Miura, T., et al. (2023) · Journal of Diabetes Investigation · doi:10.1111/jdi.13982 · Cited by 10
Lv, J., Guo, L., Wang, R., & Chen, J. (2023) · Kidney Diseases · doi:10.1159/000530395 · Cited by 12
Šitina, M., Lukeš, M., & Šrámek, V. (2023) · BMC Endocrine Disorders · doi:10.1186/s12902-023-01339-w · Cited by 10
Practical Guidance for the Use of SGLT2 Inhibitors in Heart Failure
Cavallari, I., Crispino, S. P., Segreti, A., Ussia, G. P., & Grigioni, F. (2023) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-023-00601-9 · Cited by 13
Exploring SGLT-2 Inhibitors: Benefits beyond the Glucose-Lowering Effect—What Is New in 2023?
Young, C. F., Farnoudi, N., Chen, J., & Shubrook, J. H. (2023) · Endocrines · doi:10.3390/endocrines4030045 · Cited by 14
SGLT2 inhibitors in heart failure with preserved ejection fraction
Faluk, M. A., Wardhere, A., Thakker, R. A., & Khan, F. (2024) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2024.102388 · Cited by 11
Oommen, S. G., Man, R. K., Talluri, K., Nizam, M., Kohir, T., Aviles, M. A., Nino, M., Jaisankar, L. G., Jaura, J., Wannakuwatte, R. A., et al. (2024) · Cureus · doi:10.7759/cureus.61790 · Cited by 10
Usman, M., Hamid, A., Qazi, S. U., Kosiborod, M., Bhatt, D. L., Khan, M. S., Vaduganathan, M., & Butler, J. (2024) · Global Cardiology · doi:10.4081/cardio.2024.35 · Cited by 10
Self-citationJensen, J., Poulsen, M. K., Petersen, P. W., Gerdes, B., Rossing, K., & Schou, M. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14324 · Cited by 11
Patient Mortality Following New-Onset Heart Failure Stratified by Cancer Type and Status
Nouhravesh, N., Strange, J. E., Holt, A., Tønnesen, J., Andersen, C. F., Nielsen, S. K., Køber, L., Mentz, R. J., Nielsen, D. L., Fosbøl, E. L., et al. (2023) · European Journal of Heart Failure · doi:10.1002/ejhf.2984 · Cited by 10
Earlier heart failure diagnosis in primary care
Taylor, C. J. (2022) · British Journal of General Practice · doi:10.3399/bjgp23x731481 · Cited by 10
Keidai, Y., Yoshiji, S., Hasebe, M., Minamino, H., Murakami, T., Tanaka, D., Fujita, Y., & Inagaki, N. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15122 · Cited by 12
Tao, W., Yang, X., Zhang, Q. H., Bi, S., & Yao, Z. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1181473 · Cited by 9
An updated review of experimental rodent models of pulmonary hypertension and left heart disease
Jasińska-Stroschein, M. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1308095 · Cited by 9
Fu, X., Yang, W. P., & Fang, J. (2024) · ESC Heart Failure · doi:10.1002/ehf2.14627 · Cited by 11
Duvalyan, A., Hoz, R. M. L., McGuire, D. K., & Drazner, M. H. (2024) · Journal of Cardiac Failure · doi:10.1016/j.cardfail.2024.04.009 · Cited by 12
Docherty, K. F., Buendía, R., Folkvaljon, F., de Boer, R. A., Cowie, M., Hammarstedt, A., Kitzman, D. W., Kosiborod, M., Langkilde, A. M., Reicher, B., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.012349 · Cited by 9
Self-citationOstrominski, J. W., Lassen, M. C. H., Claggett, B. L., Miao, Z. M., Inzucchi, S. E., Docherty, K. F., Desai, A. S., Jhund, P. S., Køber, L., Ponikowski, P. P., et al. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae780 · Cited by 9
Self-citationUnraveling Comorbidities Contribution to Cardiac Diastolic Dysfunction and Heart Failure
Villalba‐Orero, M., López-Olañeta, M. M., Campos-Olmo, B., Jiménez‐Carretero, D., Sánchez-García, L., Sánchez‐Cabo, F., Ausiello, A., Cañas-Álvaro, R., Camafeita, E., Vázquez, J., et al. (2024) · Circulation Heart Failure · doi:10.1161/circheartfailure.124.011724 · Cited by 9
Harris, D. D., Stone, C. R., Broadwin, M., Kanuparthy, M., Sabe, S. A., Nho, J.-W., Hamze, J., Abid, M. R., & Sellke, F. W. (2024) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2024.100532 · Cited by 9
Steatotic Liver Disease in Older Adults: Clinical Implications and Unmet Needs
Clayton‐Chubb, D., Kemp, W. W., Majeed, A., Lange, P. W., Fitzpatrick, J. A., Vaz, K., Lubel, J. S., Hodge, A. D., Ryan, J. L., McNeil, J. J., et al. (2025) · Nutrients · doi:10.3390/nu17132189 · Cited by 12
Advances in the Pharmacological Treatment of Heart Failure With Preserved Ejection Fraction
Valente, V., Beer, B. N., & Savarese, G. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2025.0111 · Cited by 9
Autoimmune liver diseases and diabetes
Jensen, A. H., Ytting, H., Winther‐Sørensen, M., Burisch, J. M., Bergquist, A. M., Gluud, L. L., & Albrechtsen, N. J. W. (2023) · European Journal of Gastroenterology & Hepatology · doi:10.1097/meg.0000000000002594 · Cited by 9
One size fits all: The story of SGLT2 inhibitors in heart failure
Verma, S., Dhingra, N. K., Bhatt, D. L., Marx, N., & Cosentino, F. (2022) · Med · doi:10.1016/j.medj.2022.10.001 · Cited by 9
Ismayl, M., Abbasi, M. A., Al-Abcha, A. K., El-Am, E. A., Lundgren, S. W., Goldsweig, A. M., & Anavekar, N. S. (2023) · Current Problems in Cardiology · doi:10.1016/j.cpcardiol.2023.101597 · Cited by 10
Sandhu, A. T., & Cohen, D. J. (2023) · JAMA Cardiology · doi:10.1001/jamacardio.2023.0087 · Cited by 9
Implantable Hemodynamic-GUIDE Monitors
Fudim, M., Butler, J., & Kittipibul, V. (2024) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2023.12.008 · Cited by 9
Ji, L., Mishra, M., & Geest, B. D. (2023) · Pharmaceutics · doi:10.3390/pharmaceutics15041092 · Cited by 8
Heart failure with preserved ejection fraction: New challenges and new hopes
Logeart, D. (2023) · La Presse Médicale · doi:10.1016/j.lpm.2023.104185 · Cited by 8
Time to SGLT2 Inhibitors Initiation in Patients With Heart Failure
Moon, J., Udell, J. A., Chong, A. S., Fang, J., Austin, P. C., Ko, D. T., Stukel, T. A., Atzema, C. L., Booth, G. L., Tu, K., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.032296 · Cited by 8
Tereshchenko, S. N., Жиров, И. В., Uskach, T. M., Saidova, M. A., Sp, G., Rimskaya, E. M., Николаевна, Н. С., Narusov, O. Y., Safiullina, A. A., Tereshchenko, A. S., et al. (2024) · Eurasian heart journal · doi:10.38109/2225-1685-2024-2-6-76 · Cited by 8
Harris, D. D., Broadwin, M., Sabe, S. A., Stone, C. R., Kanuparthy, M., Nho, J.-W., Bellam, K. G., Banerjee, D., Abid, M. R., & Sellke, F. W. (2024) · Journal of Thoracic and Cardiovascular Surgery · doi:10.1016/j.jtcvs.2024.06.004 · Cited by 8
Hou, J., Ren, L., Hou, Q., Jia, X., Mei, Z., Xu, J., Yang, Z., Li, Y., & Yan, C. (2024) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2024.1388337 · Cited by 12
Mechanism-based myofilament manipulation to treat diastolic dysfunction in HFpEF
Dominic, K. L., Schmidt, A. V., Granzier, H. L. M., Campbell, K. S., & Stelzer, J. E. (2024) · Frontiers in Physiology · doi:10.3389/fphys.2024.1512550 · Cited by 8
Emanuelsson, F., Jensen, J., Omar, M., Jürgens, M., Kistorp, C., Brandt, N., Møller, J. E., Schou, M., Bechmann, L. E., Larsen, E. L., et al. (2024) · Journal of clinical lipidology · doi:10.1016/j.jacl.2024.12.015 · Cited by 8
Meybodi, S. M. (2024) · American Journal of Cardiovascular Disease · doi:10.62347/aapz2726 · Cited by 8
Benedetti, R., Chianese, U., Papulino, C., Scisciola, L., Cortese, M., Formisano, P., Gaudio, N. D., Cabaro, S., D’Esposito, V., Pesapane, A., et al. (2025) · European Journal of Heart Failure · doi:10.1002/ejhf.3566 · Cited by 8
Novel impact of metal ion-induced cell death on diabetic cardiomyopathy pathogenesis and therapy
Jiang, J., Hu, S., Hu, K., Xiao, L., Lin, J., Chen, Y., Zhang, D., Ou, Y.-L., Zhang, J., Yuan, L., et al. (2025) · APOPTOSIS · doi:10.1007/s10495-025-02090-4 · Cited by 8
Sodium-glucose cotransporter 2 inhibitors and atherosclerosis
Ceasovschih, A., Balta, A., Aldeen, E. S., Bianconi, V., Barkas, F., Şener, Y. Z., Jakubová, M., Yılmaz, M. B., Banach, M., Șorodoc, L., et al. (2025) · American Journal of Preventive Cardiology · doi:10.1016/j.ajpc.2025.101061 · Cited by 8
SGLT2 Inhibitors in Older Adults With Cardiovascular Disease: A Systematic Review and Meta‐Analysis
Minami, K., Terashima, R., Freeman, L., Yamada, Y., Vest, A. R., Yano, Y., Naito, T., & Miyashita, S. (2025) · Journal of the American Geriatrics Society · doi:10.1111/jgs.70143 · Cited by 14
Wu, J., Tseng, K., Kao, C., Hung, K.-C., Yu, T., & Lin, Y. (2025) · Critical Care · doi:10.1186/s13054-025-05685-0 · Cited by 8
Heart Failure Statistics 2025 Update: A Report From the Korean Society of Heart Failure
Lee, C. J., Lee, H., Ko, K., Kong, M. G., Kim, M. S., Bae, S., Ahn, Y., Chun, K., Choi, K.-U., Choi, J. Y., et al. (2026) · International Journal of Heart Failure · doi:10.36628/ijhf.2026.0001 · Cited by 8
Mechanoenergetische Defekte bei Herzinsuffizienz
Maack, C. (2023) · Herz · doi:10.1007/s00059-022-05161-3 · Cited by 9
Lee, K., Noh, J. H., Park, S., Choi, K. M., Kang, S., Won, K. C., Cho, H., & Moon, M. K. (2023) · International Journal of Heart Failure · doi:10.36628/ijhf.2022.0028 · Cited by 8
Sodium-Glucose Cotransporter-2 (SGLT-2) Inhibitors in Heart Failure: An Umbrella Review
Roy, R., Vinjamuri, S., Salian, R. B., Hafeez, N., Sundaram, D. M., Patel, T., Gudi, T. R., & Vasavada, A. M. (2023) · Cureus · doi:10.7759/cureus.42113 · Cited by 8
Missed Opportunities in the Diagnosis of Heart Failure: A Real-World Assessment
Ferreira, J. P., Taveira‐Gomes, T., Canelas‐Pais, M., Phan, P., Bernardo, F., Sundell, K. A., Almeida, M., Martinho, H. M., & Gavina, C. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14531 · Cited by 8
Cheema, H. A., Shafiee, A., Athar, M. M. T., Rafiei, M. A., Mehmannavaz, A., Jafarabady, K., Shahid, A., Ahmad, A. N., Ijaz, S. H., Dani, S. S., et al. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1273781 · Cited by 9
Emerging Medical Therapies for the Treatment of Obesity in Women with Cardiovascular Diseases
Behrooz, L., Lenneman, C. G., & Hamburg, N. M. (2023) · Current Cardiology Reports · doi:10.1007/s11886-023-01961-z · Cited by 8
Soleimani, H., Saeedian, B., Pasebani, Y., Babajani, N., Pashapour‐Yeganeh, A., Bahiraie, P., Navid, H., Amin, A., Samsky, M. D., Nanna, M. G., et al. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14633 · Cited by 9
Spasovski, G. B., Rroji, M., Hristov, G., Bushljetikj, O., Spahia, N., & Bushletikj, I. R. (2024) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2023.0227 · Cited by 9
Avances en insuficiencia cardiaca
Zamorano, J. L., & Leal, A. G. (2024) · Medicina Clínica · doi:10.1016/j.medcli.2023.12.026 · Cited by 8
Kourek, C., Briasoulis, Α., Papamichail, A., Xanthopoulos, A. V., Tsougos, E., Farmakis, D. T., & PARASKEVAIDIS, I. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25063113 · Cited by 11
Geng, X., Shang, W.-Y., Qi, Z., Zhang, C., Li, W.-X., Yan, Z., Fan, X., & Zhang, J. (2024) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2024.108848 · Cited by 9
Karlström, P., Pivodic, A., Dahlström, U., & Fu, M. L. X. (2024) · Clinical Research in Cardiology · doi:10.1007/s00392-024-02498-z · Cited by 8
Kongmalai, T., Prawjaeng, J., Hadnorntun, P., Leelahavarong, P., Chaikledkaew, U., Thakkinstian, A., & Srinonprasert, V. (2024) · PharmacoEconomics - Open · doi:10.1007/s41669-024-00526-2 · Cited by 9
Tanaka, A., Imai, T., Toyoda, S., Sugimoto, K., Yoshida, R., Furuta, M., Node, K., & the PROTECT Investigators (2023) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-023-01129-3 · Cited by 8
Aetiology, ejection fraction and mortality in chronic heart failure: a mediation analysis
Fritz, J., Belovari, K., Ulmer, H., Zaruba, M., Messner, M., Ungericht, M., Siebert, U., Ruschitzka, F. T., Bauer, A., & Poelzl, G. (2023) · Heart · doi:10.1136/heartjnl-2023-322803 · Cited by 8
Marx, N., & Müller‐Wieland, D. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad282 · Cited by 8
Lin, J., Milder, T. Y., Deakin, C. T., Costa, J. D. O., Havard, A., Neuen, B. L., Buckley, N. A., Brieger, D. B., Greenfield, J. R., Jun, M., et al. (2025) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2025.112242 · Cited by 8
Parsi, S., Shirsat, P. D., Mahali, L. P., Surani, S., & Kashyap, R. (2025) · World Journal of Cardiology · doi:10.4330/wjc.v17.i10.109731 · Cited by 7
Integrating Senescence and Oxidative Stress in Cardiac Disease
Yun, H. R., Singh, M. K., Han, S., Ranbhise, J. S., Ha, J., Kim, S. S., & Kang, I. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms262411917 · Cited by 8
Next-Generation SGLT2 Inhibitors: Innovations and Clinical Perspectives
Man, D. E., Duda-Seiman, D. M., & Dragan, S. R. (2025) · Biomedicines · doi:10.3390/biomedicines14010081 · Cited by 11
Kondo, T., Jering, K., Borleffs, C. J. W., de Boer, R. A., Claggett, B. L., Desai, A. S., Dobreanu, D., Inzucchi, S. E., Hernandez, A. F., Janssens, S. P., et al. (2023) · Circulation · doi:10.1161/circulationaha.122.062918 · Cited by 9
Self-citationJhund, P. S. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15171 · Cited by 7
Self-citationFemale is Associated with Left Ventricular Diastolic Dysfunction in Patients with Type 2 Diabetes
Wang, Y., Zhou, Y., Zhang, Y., Ren, Q., Wang, Y., & Su, H. (2023) · Diabetes Metabolic Syndrome and Obesity · doi:10.2147/dmso.s421761 · Cited by 7
Tan, Y. J., Ong, S. C., & Kan, Y. M. (2023) · Applied Health Economics and Health Policy · doi:10.1007/s40258-023-00825-5 · Cited by 11
Incorporating Evidence and Guidelines for Personalized Care of Diabetes and Chronic Kidney Disease
Neumiller, J. J., Alicic, R. Z., & Tuttle, K. R. (2023) · Seminars in Nephrology · doi:10.1016/j.semnephrol.2023.151427 · Cited by 7
Kodsi, M. H., Makarious, D., Gan, G. C. H., Choudhary, P., & Thomas, L. (2023) · ESC Heart Failure · doi:10.1002/ehf2.14555 · Cited by 7
Kambič, T., Lavie, C. J., & Eijsvogels, T. M. H. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehad856 · Cited by 7
Advances in the diagnosis and treatment of transthyretin amyloid cardiomyopathy
Vaishnav, J., Brown, E. E., & Sharma, K. (2024) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2024.01.013 · Cited by 8
Ezhumalai, B., Modi, R., Panchanatham, M., & Kaliyamoorthy, D. (2024) · Indian Heart Journal · doi:10.1016/j.ihj.2024.07.005 · Cited by 10
Horiuchi, Y., Wettersten, N. W., Asami, M., Yahagi, K., Komiyama, K., Yuzawa, H., Tanaka, J., Aoki, J., & Tanabe, K. (2024) · International Journal of Cardiology · doi:10.1016/j.ijcard.2024.132611 · Cited by 8
Xiong, S., Huang, L., Liu, H., Zhang, X., Li, M., Cui, Y.-B., Shao, C., & Hu, X. (2024) · World Journal of Diabetes · doi:10.4239/wjd.v16.i2.97287 · Cited by 7
Heart failure with preserved ejection fraction therapeutics: in search of the pillars
Rafei, A. E., Harrington, J., Tavares, C. A. M., Guimarães, P. O., Ambrosy, A. P., Bonaca, M. P., Sauer, A. J., Vardeny, O., & Canonico, M. E. (2025) · Heart Failure Reviews · doi:10.1007/s10741-025-10524-z · Cited by 8
Țica, O., & Ţică, O. (2025) · Diagnostics · doi:10.3390/diagnostics15162079 · Cited by 8
Ju, F., Abbott, G. W., Li, J., Wang, Q., Liu, T., Liu, Q., & Hu, Z. (2023) · Cardiovascular Drugs and Therapy · doi:10.1007/s10557-022-07419-8 · Cited by 8
Cheng, J. W. M., Colucci, V. J., Kalus, J. S., & Spinler, S. A. (2023) · Annals of Pharmacotherapy · doi:10.1177/10600280231154021 · Cited by 8
Avgerinos, I., Karagiannis, T., Matthews, D. R., Τσάπας, Α., & Bekiari, E. (2023) · Diabetes Obesity and Metabolism · doi:10.1111/dom.15200 · Cited by 8
Bauersachs, J. K., & Soltani, S. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad540 · Cited by 8
Heart Failure and Secondary Mitral Regurgitation: A Contemporary Review
Camaj, A., Thourani, V. H., Gillam, L. D., & Stone, G. W. (2023) · Journal of the Society for Cardiovascular Angiography & Interventions · doi:10.1016/j.jscai.2023.101195 · Cited by 7
SGLT2 Inhibition in Heart Failure: Clues to Cardiac Effects?
Savage, P., Dixon, L., Grieve, D., & Watson, C. J. (2024) · Cardiology in Review · doi:10.1097/crd.0000000000000637 · Cited by 7
Henson, B. D., Bale, C., Mecaskey, R., Gbujie, O., Zhan, M., Rao, K. K., & Carbone, S. (2024) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001620 · Cited by 6
Erythropoietic response to oral iron with sodium-glucose co-transporter 2 inhibitors
Marques, P. S., Matias, P., Travlos, C. K., Angélico‐Gonçalves, A., Diniz, H., Vasques‐Nóvoa, F., Packer, M., Friões, F., Tsoukas, M. A., Mavrakanas, T. A., et al. (2025) · Clinical Research in Cardiology · doi:10.1007/s00392-025-02685-6 · Cited by 6
Grilo, R. M., & Falcão, L. M. (2025) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2025.10.013 · Cited by 9
Astragaloside IV attenuates sunitinib-associated cardiotoxicity by inhibiting COUP-TFII
Qin, W., Li, S., Cheng, Z., Xue, W., Tian, M., Mou, F.-F., Guo, H.-D., Shao, S.-J., & Liu, B. (2024) · Heliyon · doi:10.1016/j.heliyon.2024.e24779 · Cited by 6
Elliott, J., & Oyama, M. A. (2024) · Journal of Veterinary Pharmacology and Therapeutics · doi:10.1111/jvp.13472 · Cited by 6
Nilsson, C. N., Ersbøll, M. K., & Gustafsson, F. (2024) · Cardiac failure review · doi:10.15420/cfr.2023.25 · Cited by 6
Yulong, X., Jiang, J., Fan, F., Pan, Y., Zhou, J., Zhang, Y., Li, J., Liu, J., Yang, N., Hao, Y., et al. (2024) · Journal of the American Heart Association · doi:10.1161/jaha.123.033941 · Cited by 9
Meine, M. C., Santo, P. A. D. E., de Oliveira, F. D., Marques, G. L., & Barboza, J. S. (2024) · Heart Failure Reviews · doi:10.1007/s10741-024-10457-z · Cited by 6
Corrado, D., Graziano, F., Bauce, B., Marinas, M. B., Calore, C., Celeghin, R., Cipriani, A., Gaspari, M. D., Lazzari, M. D., Migliore, F., et al. (2025) · European Heart Journal Supplements · doi:10.1093/eurheartjsupp/suae108 · Cited by 6
Harris, D. D., Broadwin, M., Stone, C. D., Sabe, S. A., Kanuparthy, M., Nho, J.-W., Muir, K. C., Abid, M. R., & Sellke, F. W. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26051887 · Cited by 6
Liu, R., Qu, Z., Feng, Y., Bai, L., Liu, X. F., Fan, X., Liu, X., & Zhao, L. (2025) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2025.108981 · Cited by 6
Metadata
- Authors
- Vaduganathan, M., Docherty, K. F., Claggett, B. L., Jhund, P. S., de Boer, R. A., Hernandez, A. F., Inzucchi, S. E., Kosiborod, M. N., Lam, C. S. P., Martinez, F., Shah, S. J., Desai, A. S., McMurray, J. J. V., & Solomon, S. D.
- Affiliations
- Brigham and Women's Hospital (US)
- British Heart Foundation (GB)
- Duke Medical Center (US)
- Yale University (US)
- University of Missouri–Kansas City (US)
- National University of Singapore (SG)
- Northwestern University (US)
- Corresponding author
- Solomon, Scott D
- ORCID
- Venue
- The Lancet
- Publisher
- Elsevier BV
- Published
- 2022-09
- Volume
- 400
- Issue
- 10354
- Pages
- 757-767
- ISSN
- 0099-5355 (ISSN-L)
- 0140-6736
- OpenAlex
- W4293353625
- Cited by
- 996
- References
- 24
- Citations by year
- 2026: 215 · 2025: 203 · 2024: 279 · 2023: 257 · 2022: 42
- FWCI
- 39.76
- Type
- journal article
- Language
- en
- Update notices
- erratum (2023-01-14)
- Open access
- hybrid
- doi.org
- Licence
- Locations
- The Lancet (publishedVersion, public-domain)
- PubMed (publishedVersion)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (acceptedVersion, public-domain)
- ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (submittedVersion, public-domain)
- University of Groningen research database (University of Groningen / Centre for Information Technology) (submittedVersion, other-oa)
- Funders
- Amgen
- Eli Lilly and Company (NCT03057951)
- Pfizer
- AstraZeneca
- Sanofi
- National Institutes of Health
- Defense Acquisition Program Administration
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Heart Failure Treatment and Management
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Cardiovascular Function and Risk Factors
- Keywords
- SGLT2 inhibitors, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction, cardiovascular mortality, heart failure hospitalization, all-cause mortality, subgroup analysis, DAPA-HF, EMPEROR-Preserved, EMPEROR-Reduced, cardiovascular risk stratification, treatment effect heterogeneity
- MeSH terms
- Sodium-Glucose Transporter 2 Inhibitors, Diabetes Mellitus, Type 2, Heart Failure, Hospitalization, Humans, Stroke Volume, Randomized Controlled Trials as Topic, Ventricular Function, Left, Ventricular Dysfunction, Left
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
